RecruitingNCT03825458

Creation of a Cohort for the Quantitation and Characterization of Circulating Viral RNAs as a New Biomarker of Hepatitis B Functional Cure.

Sponsor

Hospices Civils de Lyon

Enrollment

3,500 participants

Start Date

Feb 25, 2019

Study Type

OBSERVATIONAL

Conditions

Hepatitis B

Summary

The " CirB-RNA " cohort aims to create a biological collection associated with clinical and biological data from patients with hepatitis B infection. This project is part of a much larger program that aims to characterize and quantify circulating viral RNAs as a possible new biomarker of hepatitis B functional cure.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Blood sampling for people with hepatitis b. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERBlood sampling

Blood sampling at each clinical follow-up visit.

Locations(6)

Hepatology department - Groupement Hospitalier Nord - Hôpital de la Croix-Rousse

Lyon, France

Hôpital de la Croix-Rousse - Service de maladies infectieuses et tropicales

Lyon, France

Department of Hepato-gastroenterology and pediatric nutrition - Hôpital Femme-Mère Enfant

Lyon, France

Gastroenterology and Hepatology department - • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Milan, Italy

Gastroenterology and Hepatology department - • Università degli Studi di Palermo

Palermo, Italy

Infectious diseases and hepatology unit - Azienda Ospedaliero

Parma, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03825458

Related Trials

Evaluation of Patients With Liver Disease

NCT000019711 location

Comparison of Viral Suppression With 0.5 mg and 1.0 mg Daily Doses of Entecavir in Decompensated HBV Cirrhosis of Liver

NCT07816094

National Liver Cancer Screening Trial

NCT0608423418 locations

Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer

NCT051818267 locations

Non-interventional Study to Assess the Number of People With Untreated/Unknown HBV + HDV and HCV in South-East Austria

NCT068341781 location